Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ionic Brands Corp. (IONKF)
Tacoma, WA, US
Ionic Brands Corp. is an enterprise active in Washington and Oregon, focused on the creation, branding, and distribution of various consumable cannabis products and concentrated extracts. Their product portfolio includes cannabis oils, diverse concentrates, infusions, and distillates, as well as vaporization devices. Additionally, they provide necessary hardware like cartridges, applicators, pen-style vaporizers, and storage jars. Beyond their direct product lines, the company offers a suite of support services to the wider cannabis processing and production industry. These ancillary offerings involve the rental of processing and transportation machinery, the sourcing of equipment, packaging, and labeling materials, intellectual property licensing, and comprehensive operational and marketing assistance for licensed cannabis producers and processors. Their products and services are available under the IONIC, Zoots, and Dabulous brand names. The firm maintains its primary corporate office in Tacoma, Washington.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.99% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+178.2% ★ Q4'21: +227.0% (vs Q4'20)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+94.9% ★ Q4'21: +85.9% (vs Q4'20)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-52.6% Q4'21: +17.5% (vs Q4'20)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-35.7% Q4'21: -45.4% (vs Q4'20)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-32.7% Q4'21: -36.1% (vs Q4'20)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2,926.9% Q4'21: +345.5% (vs Q4'20)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.11× Q4'21: -1.01× (vs Q4'20)
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
8.97M
est: 9.46M (-5.2%)
|
24.95M
est: 28.67M (-13.0%)
|
40.74M
est.
|
9.46M
est.
|
9.46M
9.46M – 9.46M
+0.0% YoY
|
28.67M
28.67M – 28.67M
+203.0% YoY
|
40.74M
40.74M – 40.74M
+42.1% YoY
|
| EBITDA |
-2.36M
est: -2.95M (+20.2%)
|
-5.85M
est: -8.95M (+34.6%)
|
-12.71M
est.
|
-2.95M
est.
|
-2.95M
-2.95M – -2.95M
+0.0% YoY
|
-8.95M
-8.95M – -8.95M
-203.0% YoY
|
-12.71M
-12.71M – -12.71M
-42.1% YoY
|
| EBIT |
-3.60M
est: -3.71M (+2.8%)
|
-8.91M
est: -11.23M (+20.7%)
|
-15.96M
est.
|
-3.71M
est.
|
-3.71M
-3.71M – -3.71M
+0.0% YoY
|
-11.23M
-11.23M – -11.23M
-203.0% YoY
|
-15.96M
-15.96M – -15.96M
-42.1% YoY
|
| Net Income |
-6.68M
est: -4.71M (-41.9%)
|
-10.87M
est: -12.72M (+14.6%)
|
—
est.
|
-4.71M
est.
|
-4.71M
-4.71M – -4.71M
+0.0% YoY
|
-12.72M
-12.72M – -12.72M
-170.3% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
2.68M
est: 3.95M (-32.1%)
|
3.70M
est: 11.97M (-69.0%)
|
17.00M
est.
|
3.95M
est.
|
3.95M
3.95M – 3.95M
+0.0% YoY
|
11.97M
11.97M – 11.97M
+203.0% YoY
|
17.00M
17.00M – 17.00M
+42.1% YoY
|
| EPS |
-1.34
est: -0.03 (-4,431.3%)
|
-0.07
est: -0.08 (+14.5%)
|
—
est.
|
-0.03
est.
|
-0.03
-0.03 – -0.03
+0.0% YoY
|
-0.08
-0.08 – -0.08
-170.3% YoY
|
—
— – —
+100.0% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bryen Joseph Salas | President, GM & Director | 135.3K | male |
| Christian Dante Vara | Chief Operating Officer & Director | 121.4K | male |
| Christian Drew Struzan | Co-Founder, Chief Brand Officer & Director | 94.0K | male |
| Austin Taylor Gorst | Co-Founder, Vice President of Sales, GM of Oregon & Director | 91.5K | male |
| David Croom | Chief Financial Officer | — | male |
| Joanne Salas | Chief Administrative Officer | — | female |
| Zachary Bell | Chief Science Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IONKF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
